Kiora Pharmaceuticals Secures $24M Private Placement Led by Perceptive Advisors

Funds will support ongoing R&D and strategic business development for biotech company's retinal disease therapies

Apr. 7, 2026 at 11:06am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking gears and mechanisms in shades of grey and bronze, representing the secure, industrial infrastructure of the financial system as a metaphor for the funding that will support Kiora Pharmaceuticals' drug development efforts.The private placement funding will enable Kiora Pharmaceuticals to continue advancing its pipeline of innovative retinal disease therapies.Encinitas Today

Kiora Pharmaceuticals, a clinical-stage biotech company developing treatments for retinal diseases, has closed a $24 million private placement led by Perceptive Advisors and ADAR1 Capital Management. The funding will be used to advance the company's pipeline, including its lead candidates KIO-301 for retinitis pigmentosa and KIO-104 for macular edema.

Why it matters

The private placement provides Kiora with the capital needed to continue developing its innovative small molecule therapies targeting critical pathways in retinal diseases. As the company works to bring these potential treatments to market, the funding will support ongoing R&D as well as strategic business development to expand the commercial opportunity.

The details

Under the terms of the agreement, Kiora issued shares of common stock or pre-funded warrants, along with accompanying short-term and long-term warrants that could provide up to an additional $19 million if exercised. The transaction was priced at-the-market and closed on April 6, 2026. Kiora has agreed to file a registration statement to cover the resale of the shares sold in the private placement.

  • The private placement closed on April 6, 2026.
  • Kiora plans to file a resale registration statement in the coming months.

The players

Kiora Pharmaceuticals

A clinical-stage biotechnology company developing advanced therapies for retinal diseases, including KIO-301 for retinitis pigmentosa and KIO-104 for macular edema.

Perceptive Advisors

A new investor that led the $24 million private placement in Kiora Pharmaceuticals.

ADAR1 Capital Management

An existing investor that participated in the $24 million private placement alongside Perceptive Advisors.

Got photos? Submit your photos here. ›

What’s next

Kiora plans to use the proceeds from the private placement to support ongoing research and development, as well as strategic business development activities. The company has also agreed to file a registration statement to cover the resale of the shares sold in the transaction.

The takeaway

This private placement provides Kiora Pharmaceuticals with the necessary funding to advance its pipeline of retinal disease therapies, including its lead candidates KIO-301 and KIO-104. The investment from Perceptive Advisors and ADAR1 Capital Management underscores the potential of Kiora's innovative small molecule approach to addressing critical unmet needs in ophthalmology.